Stereotaxis, Inc. (STXS, Financial) experienced a notable stock increase of 6.16%, reaching $2.33 per share with a trading volume of 280,309 shares. Despite a net loss of $6.19 million and negative earnings per share of $0.08, the company reported revenue of $9.20 million. Impressively, all four rating institutions recommend a "buy" for the stock, with no hold or sell ratings.
In the medical device sector, where Stereotaxis operates, the overall decline was 0.11%. However, companies like Avinger, Inc. and Sharps Technology Inc. saw significant gains. Stereotaxis focuses on robotic technology to enhance arrhythmia treatment and vascular procedures, with most revenue derived from disposable products and services in the U.S.
